BIAF Stock Overview
Engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
bioAffinity Technologies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.40 |
| 52 Week High | US$3.62 |
| 52 Week Low | US$0.95 |
| Beta | 0 |
| 1 Month Change | -2.04% |
| 3 Month Change | 14.29% |
| 1 Year Change | 31.87% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -71.08% |
Recent News & Updates
Shareholder Returns
| BIAF | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -10.1% | -1.2% | -1.2% |
| 1Y | 31.9% | 4.7% | 21.5% |
Return vs Industry: BIAF exceeded the US Biotechs industry which returned 4.7% over the past year.
Return vs Market: BIAF exceeded the US Market which returned 21.5% over the past year.
Price Volatility
| BIAF volatility | |
|---|---|
| BIAF Average Weekly Movement | 24.1% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: BIAF's share price has been volatile over the past 3 months.
Volatility Over Time: BIAF's weekly volatility has increased from 17% to 24% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 14 | Maria Zannes | www.bioaffinitytech.com |
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung. It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas.
bioAffinity Technologies, Inc. Fundamentals Summary
| BIAF fundamental statistics | |
|---|---|
| Market cap | US$27.86m |
| Earnings (TTM) | -US$8.37m |
| Revenue (TTM) | US$4.94m |
5.6x
P/S Ratio-3.3x
P/E RatioIs BIAF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIAF income statement (TTM) | |
|---|---|
| Revenue | US$4.94m |
| Cost of Revenue | US$3.31m |
| Gross Profit | US$1.62m |
| Other Expenses | US$9.99m |
| Earnings | -US$8.37m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.73 |
| Gross Margin | 32.88% |
| Net Profit Margin | -169.42% |
| Debt/Equity Ratio | 0.5% |
How did BIAF perform over the long term?
See historical performance and comparison